[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Moderna Inc (MRNA)

Moderna Inc (MRNA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Market News and Commentary

Moderna Stock: Is MRNA Outperforming the Health Care Sector?

With a market cap of $19.5 billion, Moderna, Inc. (MRNA) is a biotechnology company focused on developing medicines and vaccines using messenger RNA (mRNA) technology. Headquartered in Cambridge, Massachusetts, Moderna rose to global prominence with the development of one of the first COVID-19 vaccines, Spikevax, which became a major contributor to worldwide vaccination efforts during the pandemic.

Companies valued at $10 billion or more are generally considered "large-cap" stocks, and Moderna fits this criterion perfectly. Moderna's key competitive advantages lie in its pioneering mRNA technology platform, which enables the rapid development of vaccines and therapeutics across multiple disease areas. The company...

Fundamentals

See More
  • Market Capitalization, $K 18,823,528
  • Shares Outstanding, K 396,786
  • Annual Sales, $ 1,944 M
  • Annual Income, $ -2,822 M
  • EBIT $ -3,412 M
  • EBITDA $ -3,264 M
  • 60-Month Beta 1.05
  • Price/Sales 10.53
  • Price/Cash Flow N/A
  • Price/Book 2.76

Options Overview Details

View History
  • Implied Volatility 74.57% (-3.30%)
  • Historical Volatility 63.26%
  • IV Percentile 60%
  • IV Rank 41.67%
  • IV High 103.33% on 11/03/25
  • IV Low 54.03% on 08/06/25
  • Expected Move (DTE 4) 3.34 (7.04%)
  • Put/Call Vol Ratio 0.22
  • Today's Volume 56,336
  • Volume Avg (30-Day) 56,446
  • Put/Call OI Ratio 0.85
  • Today's Open Interest 703,512
  • Open Int (30-Day) 688,405
  • Expected Range 44.10 to 50.78

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 24 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-2.01
  • Number of Estimates 10
  • High Estimate $-1.32
  • Low Estimate $-2.35
  • Prior Year $-2.13
  • Growth Rate Est. (year over year) +5.63%

Price Performance

See More
Period Period Low Period High Performance
1-Month
43.90 +8.06%
on 06/02/26
59.48 -20.24%
on 05/11/26
+0.73 (+1.56%)
since 05/05/26
3-Month
43.68 +8.61%
on 05/01/26
59.48 -20.24%
on 05/11/26
-6.39 (-11.87%)
since 03/05/26
52-Week
22.28 +112.93%
on 11/21/25
59.55 -20.34%
on 03/04/26
+21.32 (+81.62%)
since 06/05/25

Most Recent Stories

More News
Why Is Moderna (MRNA) Stock Rocketing Higher Today

Why Is Moderna (MRNA) Stock Rocketing Higher Today

MRNA : 47.44 (-8.04%)
Moderna Stock: Is MRNA Outperforming the Health Care Sector?

Although Moderna has outperformed the broader health care sector over the last 12 months, analysts maintain a cautious stance on the stock’s future outlook.

XLV : 153.01 (+0.61%)
LLY : 1,131.42 (+0.55%)
MRNA : 47.44 (-8.04%)
Moderna to Present at Upcoming Conference in June 2026

CAMBRIDGE, MA / ACCESS Newswire / June 2, 2026 / Moderna, Inc. (Nasdaq:MRNA), today announced its participation in the following upcoming investor conference:

MRNA : 47.44 (-8.04%)
Option Volatility And Earnings Report For June 1-5

Earnings season is winding down, but we still have a couple of big name companies reporting. This week we have Broadcom, Crowdstrike, Palo Alto Networks, Medtronic and Ciena Corp all reporting.

CIEN : 488.21 (-8.85%)
MSFT : 416.67 (-2.66%)
AVGO : 385.73 (-7.92%)
CRWD : 671.02 (-6.68%)
TSLA : 391.00 (-6.56%)
MU : 864.01 (-13.25%)
MDT : 81.67 (-0.32%)
MRNA : 47.44 (-8.04%)
CRM : 185.66 (-1.64%)
Moderna and Merck Present 5-Year Data for Intismeran Autogene in Combination With KEYTRUDA (pembrolizumab) in Patients With High-Risk Stage III/IV Melanoma Following Complete Resection at the 2026 ASCO Annual Meeting

At a median 5-year (60.3 months) planned follow-up of the Phase 2b KEYNOTE-942/mRNA-4157-P201 study, intismeran autogene in combination with KEYTRUDA demonstrated a 49% reduction in the risk of recurrence...

MRK : 120.79 (+0.44%)
MRNA : 47.44 (-8.04%)
Moderna and CEPI Expand Strategic Collaboration to Advance Potential Vaccine Against Bundibugyo Ebolavirus

Coalition for Epidemic Preparedness Innovations funding builds on Moderna's prior filovirus research and supports preclinical development and Phase 1 clinical evaluation

MRNA : 47.44 (-8.04%)
NIH Infectious Disease Chief Steps Down Amid Ebola and Hantavirus Response Concerns

The acting director of the National Institute of Allergy and Infectious Diseases resigned ahead of a Senate hearing Thursday, adding to leadership turnover across U.S. health agencies during ongoing Ebola...

GILD : 129.16 (-0.02%)
MRNA : 47.44 (-8.04%)
PFE : 26.04 (+1.36%)
3 Cash-Burning Stocks with Open Questions

3 Cash-Burning Stocks with Open Questions

CLAR : 2.87 (+0.35%)
PRPL : 0.3937 (-3.74%)
MRNA : 47.44 (-8.04%)
2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds

2 Healthcare Stocks Worth Investigating and 1 Facing Headwinds

BTSG : 57.40 (unch)
MRNA : 47.44 (-8.04%)
ISRG : 422.06 (+0.77%)
FDA Commissioner Marty Makary Resigns Amid Leadership Turmoil and Biotech Industry Backlash

US Food and Drug Administration Commissioner Marty Makary is resigning after 13 months in the role, according to President Donald Trump, marking another leadership shakeup across federal health agencies....

KO : 79.48 (+3.46%)
MRNA : 47.44 (-8.04%)
AMGN : 349.58 (+1.15%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 8% Buy with a Weakest short term outlook on maintaining the current direction.

Relative Strength just crossed below 50%. The market is indicating support for a bearish trend.

See More Share

Business Summary

Moderna, Inc. is a clinical-stage pharmaceutical company, primarily focused on discovering and developing messenger RNA (mRNA) based therapies. The company's mRNA based COVID-19 vaccine, Spikevax (mRNA-1273), is approved for use in adults in the United States. The vaccine is also authorized for emergency...

See More

Key Turning Points

3rd Resistance Point 55.67
2nd Resistance Point 53.60
1st Resistance Point 50.52
Last Price 47.44
1st Support Level 45.37
2nd Support Level 43.30
3rd Support Level 40.22

See More

52-Week High 59.55
Last Price 47.44
Fibonacci 61.8% 45.31
Fibonacci 50% 40.92
Fibonacci 38.2% 36.52
52-Week Low 22.28

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.